Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Stock Statistics & Valuation Metrics

Shandong Xinhua Pharmaceutical Company Limited Class H has a market cap or net worth of HK$9.12B. The enterprise value is HK$6.69B.

Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shandong Xinhua Pharmaceutical Company Limited Class H’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.03%.

The current PE Ratio of Shandong Xinhua Pharmaceutical Company Limited Class H is 36.2. Shandong Xinhua Pharmaceutical Company Limited Class H’s PEG ratio is -0.36.

In the last 12 months, Shandong Xinhua Pharmaceutical Company Limited Class H had revenue of 8.75B and earned 289.89M in profits. Earnings per share was 0.42.

In the last 12 months, operating cash flow was 418.12M and capital expenditures -94.83M, giving a free cash flow of 323.49M billion.

Shandong Xinhua Pharmaceutical Company Limited Class H pays an annual dividend of HK$0.172, resulting in a dividend yield of 2.78%

Shandong Xinhua Pharmaceutical Company Limited Class H upcoming earnings date is Aug 26, 2026, TBA (Confirmed).

Shandong Xinhua Pharmaceutical Company Limited Class H as a current ratio of 1.43, with Debt / Equity ratio of 36.25%

In the past 12 months, Shandong Xinhua Pharmaceutical Company Limited Class H has paid 52.61M in taxes.

Shandong Xinhua Pharmaceutical Company Limited Class H EV to EBITDA ratio is 4.04, with an EV/FCF ratio of 9.56.

Shandong Xinhua Pharmaceutical Company Limited Class H has HK$1.27B in cash and marketable securities with HK$1.93B in debt, giving a net cash position of -HK$660.43M billion.

Gross margin is 18.63%, with operating margin of 4.16%, and net profit margin of 3.31%.

The average price target for Shandong Xinhua Pharmaceutical Company Limited Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―